Page 86 - 《中国药房》2025年5期
P. 86

Chem Neurosci,2020,11(17):2506-2512.                Quality of life assessment in older adults with dementia:a
          [ 8 ]  中华医学会神经病学分会帕金森病及运动障碍学组,中                          systematic review[J]. Dement Geriatr Cogn Disord,2021,
               国医师协会神经内科医师分会帕金森病及运动障碍学                             50(2):103-110.
               组,陈海波,等. 中国帕金森病早期运动症状治疗循证医                     [17]  RUOTOLO I,SELLITTO G,BERARDI A,et al. Psycho‐
               学指南[J]. 中国神经免疫学和神经病学杂志,2021,28                      metric  properties  of  the  Parkinson’s  disease  Question‐
              (4):267-279.                                         naire-39 and its short form Parkinson’s disease Question‐
               Parkinson’s  Disease  and  Movement  Disorders  Group,   naire-8:a  systematic  review  and  meta-analysis[J].  J  Clin
               Neurology Branch, Chinese Medical Association,Parkin‐  Neurosci,2024,123:100-117.
               son’s  Disease  and  Movement  Disorder  Section  of  Neu‐  [18]  MENG  J,DU  J  Y,DIAO  X  L,et  al.  Effects  of  an
               rologist  Branch  of  Chinese  Medical  Doctor Association,  evidence-based nursing intervention on prevention of anxie-
               CHEN H B,et al. Evidence-based medical guidelines for   ty  and  depression  in  the  postpartum  period[J].  Stress
               the treatment of early motor symptoms of Parkinson’s    Health,2022,38(3):435-442.
               disease in China[J]. Chin J Neuroimmunol Neurol,2021,  [19]  American  Psychiatric  Association.  The  diagnostic  and
               28(4):267-279.                                      statistical  manual  of  mental  disorders[M].  5th  edition.
          [ 9 ]  PRINGSHEIM T,DAY G S,SMITH D B,et al. Dopami‐     Washington:American Psychiatric Publishing  Inc,2013:
               nergic therapy for motor symptoms in early Parkinson di-   50-59.
               sease  practice  guideline  summary:a  report  of  the  AAN   [20]  李全伟,王爱枝,景小丽. 帕金森病应用多巴胺受体激动
               guideline  subcommittee[J].  Neurology,2021,97(20):  剂联合左旋多巴治疗的临床效果分析[J]. 首都食品与医
               942-957.                                            药,2019,26(21):76-77.
          [10]  JIANG  D  Q,JIANG  L  L,WANG Y,et  al.  The  role  of   LI Q W,WANG A Z,JING X L. Clinical effect of dopa‐
               pramipexole  in  the  treatment  of  patients  with  depression   mine receptor agonist combined with levodopa in the treat‐
               and  Parkinson’s  disease:a  meta-analysis  of  randomized   ment  of  Parkinson’s  disease[J].  J  Pharm  Res,2019,26
               controlled trials[J]. Asian J Psychiatr,2021,61:102691.  (21):76-77.
          [11]  陈永平,商慧芳 . 2016 中国帕金森病诊断标准解读[J].               [21]  ARMSTRONG  M  J,OKUN  M  S.  Diagnosis  and  treat‐
               中国实用内科杂志,2017,37(2):124-126.                        ment of Parkinson’s disease:a review[J]. JAMA,2020,
               CHEN Y P,SHANG H F. Introduction of clinical diagnostic   323(6):548-560.
               criteria for Parkinson’s disease in China 2016[J]. Chin J   [22]  HUANG  J  Z,HONG  W,YANG  Z  L,et  al.  Efficacy  of
               Pract Intern Med,2017,37(2):124-126.                pramipexole combined with levodopa for Parkinson’s di-
          [12]  ZHUPARRIS  A,THIJSSEN  E,ELZINGA  W  O,et  al.     sease treatment and their effects on QOL and serum TNF-α
               Treatment  detection  and  movement  disorder  society-  levels[J]. J Int Med Res,2020,48(7):300060520922449.
               unified  Parkinson’s  disease  rating  scale,part  Ⅲ  estima‐  [23]  徐七,李丹,彭小妍,等. 普拉克索联合多巴丝肼对帕金
               tion using finger tapping tasks[J]. Mov Disord,2023,38  森病患者认知功能、氧化应激指标及 Hcy 的影响[J]. 中
              (10):1795-1805.                                      外医学研究,2024,22(3):107-110.
          [13]  刘庆华,何金,王萌. 蒙特利尔认知量表与洛文斯顿认知                         XU  Q,LI  D,PENG  X Y,et  al.  Effects  of  pramipexole
               评定量表在脑梗死患者中的应用效果分析[J]. 齐鲁护理                         combined  with  levodopa  and  benserazide  hydrochloride
               杂志,2022,28(19):150-152.                             on cognitive function,oxidative stress indexes and Hcy in
               LIU Q H,HE J,WANG M. Analysis of the application ef‐  patients  with  Parkinson’s  disease[J].  Chin  Foreign  Med
               fect of Montreal cognitive scale and Livingston cognitive   Res,2024,22(3):107-110.
               assessment scale in patients with cerebral infarction[J]. J   [24]  杨顺利,徐辉. 普拉克索联合苯海索对帕金森病患者认
               Qilu Nurs,2022,28(19):150-152.                      知功能及生活质量的影响[J]. 临床医学研究与实践,
          [14]  史悦,高小夏,谈笑,等. 中文版认知障碍简要测试量表                         2022,7(6):71-73.
               与简易精神状态检查量表在脑卒中患者认知评估中的比                            YANG S L,XU H. Effects of pramipexole combined with
               较分析[J]. 重庆医科大学学报,2021,46(11):1310-1314.             benhexol on cognitive function and quality of life in pa‐
               SHI Y,GAO X X,TAN X,et al. Comparative analysis of   tients with Parkinson’s disease[J]. Clin Res Pract,2022,7
               brief assessment of impaired cognition(Chinese version)   (6):71-73.
               and  mini  mental  state  examination  scales  in  cognitive       [25]  张琳瑶,刘丽旭. 多巴胺受体激动剂在缺血性脑损伤后
               assessment of stroke patients[J]. J Chongqing Med Univ,  脑保护研究进展[J]. 中国卒中杂志,2024,19(10):1215-
               2021,46(11):1310-1314.                              1220.
          [15]  HENDERSHOTT T R,ZHU D,LLANES S,et al. Com‐         ZHANG L Y,LIU L X. Progress in the study of dopamine
               parative sensitivity of the MoCA and Mattis dementia ra-   receptor agonists for brain protection after ischemic brain
               ting scale-2 in Parkinson’s disease[J]. Mov Disord,2019,  injury[J]. Chin J Stroke,2024,19(10):1215-1220.
               34(2):285-291.                                               (收稿日期:2024-05-30  修回日期:2025-01-06)
          [16]  BURKS H B,DES BORDES J K A,CHADHA R,et al.                                        (编辑:胡晓霖)


          · 588 ·    China Pharmacy  2025 Vol. 36  No. 5                               中国药房  2025年第36卷第5期
   81   82   83   84   85   86   87   88   89   90   91